 AMRYT PHARMA PLCAmryt or the CompanyNOTIFICATION OF CANCELLATION OF ADMISSION TO EURONEXT GROWTHDUBLIN, Ireland, and Boston MA, August 11, 2020, Amryt, Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP, a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces that it has given Euronext Dublin Euronext notice of its intention to cancel the admission of the Companys Ordinary Shares Ordinary Shares to trading on the Euronext Growth Market Cancellation. The last day of trading in Ordinary Shares on the Euronext Growth Market will be September 8, 2020 and the Cancellation will take effect at 7.00 a.m. on September 9, 2020.The Cancellation applies only to the Euronext Growth Market and will have no effect on the companys American Depositary Shares ADSs which trade on the NASDAQ Global Select Market NASDAQ under the symbol AMYT or on Amryts Ordinary Shares trading on the AIM market of the London Stock Exchange.EnquiriesAmryt Pharma plc353 1 518 0200 Joe Wiley, CEO Rory Nealon, CFOCOO LifeSci Advisors, LLC1 212 915 2564 Tim McCarthy Consilium Strategic Communications44 0 20 3709 5700 Amber Fennell, Matthew Neal, Ashley Tapp About AmrytAmryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.Amryts commercial business comprises two orphan disease products.Juxtapid Lojuxta lomitapide is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia HoFH in the US, Canada, Columbia, Argentina and Japan under the trade name Juxtapid and in the EU under the trade name Lojuxta. HoFH is a rare genetic disorder which impairs the bodys ability to remove low density lipoprotein LDL cholesterol bad cholesterol from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature cardiovascular disease.Myalept Myalepta metreleptin is approved in the US under the trade name Myalept as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy GL and in the EU under the trade name Myalepta for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy PL in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. Metreleptin is also approved for lipodystrophy in Japan. Generalised and partial lipodystrophy are rare disorders characterised by loss or lack of adipose tissue resulting in the deficiency of the hormone leptin, produced by fat cells and are associated with severe metabolic abnormalities including severe insulin resistance, diabetes, hypertriglyceridemia and fatty liver disease.Amryts lead development candidate, FILSUVEZ is a potential treatment for the cutaneous manifestations of Epidermolysis Bullosa EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. FILSUVEZ has been granted Rare Pediatric Disease Designation and has also received a Fast Track Designation from the U.S. Food and Drug Administration. The European and US market opportunity for EB is estimated by the Company to be in excess of 1.0 billion.In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders. For more information on Amryt, including products, please visit announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation EU 5962014.The person making this notification on behalf of Amryt is Rory Nealon, CFOCOO and Company Secretary.Financial Advisors Shore Capital Edward Mansfield, Daniel Bush, John More are NOMAD and Joint Broker to Amryt in the UK. Stifel Ben Maddison are Joint Broker to the company in the UK. Davy John Frain, Daragh OReilly act as Euronext Growth advisor and Joint Broker to the company in Dublin.Forward-Looking Statements Statements in this announcement with respect to Amryts business, strategies, timing for completion of and announcing results from the EASE study, the potential impact of closing enrollment in the EASE study, as well as other statements that are not historical facts are forward-looking statements involving risks and uncertainties which could cause the actual results to differ materially from such statements. Statements containing the words expect, anticipate, intends, plan, estimate, aim, forecast, project and similar expressions or their negative identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryts present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond each of Amryts ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryts ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management. 